High-Throughput Screening for Bioactive Peptides
Cellecta has developed a revolutionary new high throughput technology for the functional screening of hundreds of thousands of bioactive peptide compounds in a single cell-based assay. Based on the combined uses of pooled lentiviral peptide libraries, FACS sorting of reporter cell lines demonstrating modulation of specific signaling pathways, and HT sequencing for identification of functional peptides enriched in the sorted cell fractions, this powerful technology can be used to discover peptide-based drugs in the newest "druggable space."
The advantages of using Cellecta's peptide screening method over other methods include:
- Cost-effective HTS of 50K-100K peptides for biological activity with pooled peptide lentiviral libraries
- Efficient delivery and expression of peptides in a wide range of reporter cell lines with lentiviral vectors
- HTS and optimization of functional peptide activity and stability with different scaffolds and fusions
- Rational in silico design of biologically active peptides based on evolutionarily conserved protein folds from all known extracellular proteins of eukaryotic, prokaryotic, and viral origin
- New druggable space for unbiased discovery of peptide-based drugs for cell surface targets in a cell-based assay
Cell-based screens with pooled peptide effector libraries will provide a unique, cost-effective alternative to existing small molecule drug libraries and can even be used by small research groups for HTS of lead peptide compounds.
- Pooled Peptide Libraries in lentiviral vectors (premade and custom)
- Cell-based HTS of Bioactive Peptides with Pooled Peptide Libraries
- Reporter Cell Line Development for HTS Screens
- Validation of Peptide Hits in Secondary Screen
- Rational Directed Evolution for Peptide Lead Optimization
- Peptide Lead Prioritization in ex vivo Mouse Models
For more information on the technology behind Cellecta's pooled peptide libraries, visit the Peptide Library Technology page.
The pooled peptide libraries were developed in collaboration with Dr. Venkatesh Natarajan and Dr. Andrei Gudkov from the Roswell Park Cancer Institute.
Back to Top